The combination of RBC–MoSe2 with anti-PD-1 immunotherapy prevented the activation of the PD-1/PD-L1 pathway to avoid immune failure and stopped the transmission of an antiapoptotic signal to tumor cells, indicating the specific immune responses to CT 26 colorectal tumor. This evidence concerns the gene CD274 and colorectal neoplasm.